13.41 % to Target, Stifel Nicolaus Reconfirms ‘Buy’ Rating on Loxo Oncology (NASDAQ:LOXO) Shares Today

May 17, 2018 - By Margaret Downey

Loxo Oncology, Inc. (NASDAQ:LOXO) Logo

Investors sentiment decreased to 0.97 in 2017 Q4. Its down 0.76, from 1.73 in 2017Q3. It turned negative, as 29 investors sold Loxo Oncology, Inc. shares while 43 reduced holdings. 23 funds opened positions while 47 raised stakes. 124.82 million shares or 329.48% more from 29.06 million shares in 2017Q3 were reported.

Ubs Asset Mgmt Americas reported 0.02% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Axa stated it has 99,836 shares. Dekabank Deutsche Girozentrale has invested 0.01% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Deutsche Comml Bank Ag reported 128,669 shares. Denver Invest Advsr Limited Liability Co has 0.02% invested in Loxo Oncology, Inc. (NASDAQ:LOXO) for 4,692 shares. Qs Ltd invested in 0% or 1,400 shares. Jpmorgan Chase And reported 0% stake. Voya Management Ltd stated it has 0.06% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Prudential Finance Inc owns 0% invested in Loxo Oncology, Inc. (NASDAQ:LOXO) for 38,070 shares. Metropolitan Life Ins Ny has invested 0.01% in Loxo Oncology, Inc. (NASDAQ:LOXO). Legal And General Gp Pcl stated it has 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). The Illinois-based Driehaus Mgmt Lc has invested 1.83% in Loxo Oncology, Inc. (NASDAQ:LOXO). Blackrock holds 0.01% or 1.84M shares. California State Teachers Retirement Sys reported 36,033 shares stake. Commercial Bank Of Montreal Can holds 458 shares.

Since December 8, 2017, it had 0 insider purchases, and 22 sales for $74.63 million activity. $158,504 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by Burstein Jennifer. $20.63M worth of stock was sold by ORBIMED ADVISORS LLC on Friday, December 8. 3,082 shares were sold by Van Naarden Jacob, worth $423,515 on Monday, May 14. $20.13 million worth of Loxo Oncology, Inc. (NASDAQ:LOXO) shares were sold by AISLING CAPITAL III LP. $1.50M worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by Naider Avi Z. on Monday, January 22. Kunkel Lori Anne sold $663,378 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) on Friday, April 20.

Loxo Oncology (NASDAQ:LOXO) Rating Reaffirmed

Stifel Nicolaus now has a $190 target on shares of Loxo Oncology (NASDAQ:LOXO). The target indicates a potential upside of 13.41 % from the current stock price of Loxo Oncology (NASDAQ:LOXO). This rating was revealed in analysts note on Thursday morning.

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

Among 6 analysts covering Loxo Oncology (NASDAQ:LOXO), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Loxo Oncology has $151 highest and $102.0 lowest target. $126.60’s average target is -24.43% below currents $167.53 stock price. Loxo Oncology had 9 analyst reports since November 28, 2017 according to SRatingsIntel. On Wednesday, March 21 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. The firm earned “Buy” rating on Wednesday, May 9 by Stifel Nicolaus. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) has “Buy” rating given on Thursday, March 1 by Stifel Nicolaus. The rating was initiated by Oppenheimer with “Buy” on Thursday, February 22. Morgan Stanley upgraded the stock to “Overweight” rating in Monday, April 16 report. The firm earned “Buy” rating on Monday, March 5 by Citigroup. BTIG Research maintained the shares of LOXO in report on Wednesday, December 20 with “Buy” rating.

The stock increased 20.09% or $28.03 during the last trading session, reaching $167.53. About 2.68 million shares traded or 559.14% up from the average. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 146.80% since May 18, 2017 and is uptrending. It has outperformed by 135.25% the S&P500.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $5.04 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

More notable recent Loxo Oncology, Inc. (NASDAQ:LOXO) news were published by: Globenewswire.com which released: “Loxo Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” on May 07, 2018, also Globenewswire.com with their article: “Loxo Oncology to Announce First Quarter 2018 Financial Results” published on May 01, 2018, Nasdaq.com published: “Loxo Oncology Reports First Quarter 2018 Financial Results” on May 08, 2018. More interesting news about Loxo Oncology, Inc. (NASDAQ:LOXO) were released by: Nasdaq.com and their article: “Mid-Afternoon Market Update: Dow Turns Lower; JC Penney Shares Plunge” published on May 17, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” with publication date: May 17, 2018.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: